Skip to main content
Fig. 1 | Cancer & Metabolism

Fig. 1

From: Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models

Fig. 1

Sulfasalazine, xCT inhibitor, sensitizes to cisplatin chemotherapeutic drugs to kill CCA cells. a Percentage of CCA cell survival after cells were treated with various concentrations of sulfasalazine, b cisplatin, and c gemcitabine in CCA cell lines KKU-213 and KKU-100. This was determined by a Cell Titer-Glo luminescence cell viability kit. d CCA cells treated with a combination of cisplatin or e gemcitabine and sulfasalazine: the luminescence signal of living cells was detected and calculated to be the cell survival percentage as shown in the bar graph. f A cell population stained with PI and annexin-5 after drug treatment detected by flow cytometry in KKU-213 cell line. Data are the mean ± standard deviation of independent, triplicate experiments

Back to article page

Cancer & Metabolism

ISSN: 2049-3002